These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 32910820)

  • 1. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies.
    Zhou T; Su TT; Mudianto T; Wang J
    J Exp Med; 2020 Oct; 217(10):. PubMed ID: 32910820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
    Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
    Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adaptive immunity against SARS-CoV-2].
    Combadière B
    Med Sci (Paris); 2020 Oct; 36(10):908-913. PubMed ID: 32960167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphopenia in COVID-19: Therapeutic opportunities.
    Fathi N; Rezaei N
    Cell Biol Int; 2020 Sep; 44(9):1792-1797. PubMed ID: 32458561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19: immunopathogenesis and Immunotherapeutics.
    Yang L; Liu S; Liu J; Zhang Z; Wan X; Huang B; Chen Y; Zhang Y
    Signal Transduct Target Ther; 2020 Jul; 5(1):128. PubMed ID: 32712629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.
    Rokni M; Ghasemi V; Tavakoli Z
    Rev Med Virol; 2020 May; 30(3):e2107. PubMed ID: 32267987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm.
    Nowill AE; de Campos-Lima PO
    J Immunol; 2020 Nov; 205(10):2566-2575. PubMed ID: 32958687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapies for COVID-19: lessons learned from sepsis.
    Remy KE; Brakenridge SC; Francois B; Daix T; Deutschman CS; Monneret G; Jeannet R; Laterre PF; Hotchkiss RS; Moldawer LL
    Lancet Respir Med; 2020 Oct; 8(10):946-949. PubMed ID: 32444269
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunology of COVID-19: Current State of the Science.
    Vabret N; Britton GJ; Gruber C; Hegde S; Kim J; Kuksin M; Levantovsky R; Malle L; Moreira A; Park MD; Pia L; Risson E; Saffern M; Salomé B; Esai Selvan M; Spindler MP; Tan J; van der Heide V; Gregory JK; Alexandropoulos K; Bhardwaj N; Brown BD; Greenbaum B; Gümüş ZH; Homann D; Horowitz A; Kamphorst AO; Curotto de Lafaille MA; Mehandru S; Merad M; Samstein RM;
    Immunity; 2020 Jun; 52(6):910-941. PubMed ID: 32505227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulated adaptive immune response contributes to severe COVID-19.
    Yu K; He J; Wu Y; Xie B; Liu X; Wei B; Zhou H; Lin B; Zuo Z; Wen W; Xu W; Zou B; Wei L; Huang X; Zhou P
    Cell Res; 2020 Sep; 30(9):814-816. PubMed ID: 32759967
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
    Schijns V; Lavelle EC
    Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe COVID-19: what have we learned with the immunopathogenesis?
    Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M
    Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019].
    Chen C; Zhang XR; Ju ZY; He WF
    Zhonghua Shao Shang Za Zhi; 2020 Jun; 36(6):471-475. PubMed ID: 32114747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [COVID-19: Pathogenesis of a multi-faceted disease].
    Bonny V; Maillard A; Mousseaux C; Plaçais L; Richier Q
    Rev Med Interne; 2020 Jun; 41(6):375-389. PubMed ID: 32507520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-Mediated Immune Responses to COVID-19 Infection.
    Guihot A; Litvinova E; Autran B; Debré P; Vieillard V
    Front Immunol; 2020; 11():1662. PubMed ID: 32719687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies.
    Bergmann CC; Silverman RH
    Cleve Clin J Med; 2020 Jun; 87(6):321-327. PubMed ID: 32366502
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanistic inferences from clinical reports of SARS-CoV-2.
    Jenkins MM; McCaw TR; Goepfert PA
    Infect Dis (Lond); 2020 Aug; 52(8):527-537. PubMed ID: 32459123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.
    Mansourabadi AH; Sadeghalvad M; Mohammadi-Motlagh HR; Rezaei N
    Life Sci; 2020 Oct; 258():118185. PubMed ID: 32750438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.
    Gatto L; Franceschi E; Nunno VD; Brandes AA
    Immunotherapy; 2020 Oct; 12(15):1111-1114. PubMed ID: 32594820
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).
    Chang FY; Chen HC; Chen PJ; Ho MS; Hsieh SL; Lin JC; Liu FT; Sytwu HK
    J Biomed Sci; 2020 Jun; 27(1):72. PubMed ID: 32498686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.